← Eichor
Study identifier: NCT07491848 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D

Condition: HEPATITIS B CHRONIC · Hepatitis D · Periodontitis  ·  Sponsor: Research Center of Periodontal-Systemic Interactions

PhaseN/A
Planned participants25
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

Periodontal disease is a chronic inflammatory condition associated with systemic diseases, highlighting the concept of periodontal medicine. This study aims to investigate the relationship between periodontal inflammation, oral lesions, and hepatitis B+D infection, with or without bulevirtide treatment. Oral-periodontal clinical parameters and targeted inflammatory biomarkers in saliva and gingival crevicular fluid will be evaluated in three groups: patients with hepatitis B+D receiving bulevirtide, patients with hepatitis B+D not receiving bulevirtide, and healthy controls.

This description comes directly from the study's public registry record.

Talk to the study team

Petra Surlin, Professor  ·  0040745538483  ·  petra.surlin@umfcv.ro

Always discuss trial participation with your own doctor first.

Locations (2)

Clinical Emergency County Hospital CraiovaCraiova, RomaniaRecruiting
University of Medicine and Pharmacy of CraiovaCraiova, RomaniaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07491848